BC Cancer Protocol Summary for Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma Using Imiquimod

**Protocol Code**
SMIMI

**Tumour Group**
Skin and Melanoma

**Contact Physician**
Dr. Vincent Ho

**ELIGIBILITY:**

**Patients must have:**
- In-transit melanoma metastases, or
- Cutaneous lymphoma, or
- Basal cell carcinoma, and
- Unsuitable for surgery, radiation therapy, or systemic chemotherapy

**Note:**
- Only reimbursable when prescribed by BC Cancer dermatologic oncology physicians

**EXCLUSIONS:**

None

**TESTS:**

A skin biopsy is customarily (but not always) required to establish the diagnosis prior to treatment

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>imiquimod 5% cream pump Or imiquimod 5% cream packets</td>
<td>Once daily for 1-3 months depending on response*</td>
<td>Apply externally</td>
</tr>
</tbody>
</table>

*If effective, may require ongoing use.
DOSE MODIFICATIONS:
None

PRECAUTIONS:
1. **Photosensitivity**: May increase sunburn susceptibility. Patients should protect themselves from the sun and artificial forms of sunlight.
2. **Local inflammatory reactions**: Intense local inflammatory reactions may occur after a few applications and may be accompanied by systemic flu-like symptoms (fever, malaise, myalgia); reactions may extend beyond the application site. Interruption of therapy may be necessary if severe.
3. **Drug interactions**: Imiquimod is not recommended for use concurrently with immunosuppressive drugs such as tacrolimus, pimicrolimus, mycophenolate mofetil, cyclosporine or methotrexate. Concomitant use of corticosteroids with imiquimod may potentially limit efficacy.

Call Dr. Vincent Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

**Melanoma metastasis:**

**Cutaneous lymphoma:**

**Basal cell carcinoma:**